Skip main navigation

Cookies Notification

We use cookies on this site to enhance your user experience. By continuing to browse the site, you consent to the use of our cookies. Learn More
×

System Upgrade on Tue, May 28th, 2024 at 2am (EDT)

Existing users will be able to log into the site and access content. However, E-commerce and registration of new users may not be available for up to 12 hours.
For online purchase, please visit us again. Contact us at customercare@wspc.com for any enquiries.

SEARCH GUIDE  Download Search Tip PDF File

  • articleNo Access

    General News

      Increased Flu Vaccine Production to Guard against SARS.

      First Simultaneous Pancreas-Kidney Transplant in Japan.

      Multimillion Dollar Life Sciences Facility in Okinawa.

      New Zealand Focuses on Biomaterials Production.

      Singapore Government's Initiatives for Life Sciences.

    • articleNo Access

      BIOBOARD

        SINGAPORE – Intelligent Sensor Informs You to Change a Diaper via SMS

        JAPAN – Tokyo Institute of Technology research: Key genetic event underlying fin-to-limb evolution

        ISRAEL – Independent Results Show that BiondVax's Universal Flu Vaccine Administered in a Trial 3 Years ago Improves Immunogenicity against Current Flu H3N2 Epidemic

        UNITED KINGDOM – Imperial Innovations Launches Orthonika: A Novel Knee Meniscus Replacement

        UNITED KINGDOM – New Vaccine For Chlamydia to Use Synthetic Biology

        CANADA – Aeterna Zentaris Announces Data and Safety Monitoring Board Scheduled to Complete Second Interim Analysis of the ZoptEC Phase 3 Trial in Endometrial Cancer in Early October

        UNITED STATES – NueMD Launches Free ICD-10 Training Tool Ahead of October 1 Deadline

        UNITED STATES – A new hope for Moderate and Severe Dementia: Upsher-Smith receives FDA approval for generic version of Namenda (Memantine HCL) Tablets

        UNITED STATES – FDA Approves U.S. Product Labeling Update for Sprycel® (dasatinib) to Include Five-Year First-Line and Seven-Year Second-Line Efficacy and Safety Data in Chronic Myeloid Leukemia in Chronic Phase